Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2

Conditions

Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Spondylitis, Ankylosing 1Hodgkin Disease 1

Interventions

Dexamethasone 337Bortezomib 187Lenalidomide 186Cyclophosphamide 166Melphalan 124Calcium Dobesilate 108daratumumab 95fludarabine phosphate 69carfilzomib 69pomalidomide 68Peripheral Blood Stem Cell Transplantation 64Filgrastim 56Thalidomide 55Busulfan 53Mycophenolic Acid 52Tacrolimus 45Granulocyte Colony-Stimulating Factor 45ixazomib 43fludarabine 42Whole-Body Irradiation 40Cyclosporine 35Etoposide 33dexamethasone acetate 31Antilymphocyte Serum 31isatuximab 29dexamethasone 21-phosphate 26Prednisone 26elotuzumab 25Biopsy 25auricularum 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Multiple Myeloma × Meloxicam × Clear all
NCT02078102 2021-02-21

A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma

Indiana University

Phase 2 Completed
38 enrolled 15 charts
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT02003625 2020-05-18

Meloxicam vs Placebo for Mobilization

Massachusetts General Hospital

Phase 2 Completed
31 enrolled 10 charts
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡